What is the 13F Pro Quality Score for ECOR?

13F Pro ranks electroCore, Inc. (ECOR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ECOR's current score at https://13fpro.ai/research/ECOR (free sign-up required for the full ranking).

Where does 13F Pro source ECOR data?

All electroCore, Inc. fundamentals and ownership data come directly from SEC EDGAR. electroCore, Inc. files with the SEC under CIK 1560258. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ECOR in?

electroCore, Inc. (ECOR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ECOR research updated on 13F Pro?

ECOR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

electroCore, Inc.(ECOR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1560258 ECOR stock profile & AI dashboard →

13F Pro Quality Score

27.4/100

Rank #2,468 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.8/100

Profitability

11.2/100

Balance Sheet

1.0/100

Earnings Quality

30.0/100

Free Cash Flow

11.6/100

Institutional Flow

25.2/100

Revenue Scale

8.0/100

Dilution Risk

23.1/100

ECOR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for electroCore, Inc. (ECOR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ECOR at 27.4/100 on a 32-signal composite quality model, placing it at rank #2,468 of 2,879 stocks — the bottom half of the AI-ranked universe. ECOR scores in the top quartile across revenue growth (90.8). Areas of concern include balance sheet strength (1.0) and revenue scale (8.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), electroCore, Inc. reports quarterly revenue of $9.6M, net income of $-5.3M, free cash flow of $-3.0M. Top institutional holders of ECOR by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BALYASNY ASSET MANAGEMENT L.P., GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. ECOR trades on the Nasdaq exchange and files with the SEC under CIK 1560258. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ECOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for electroCore, Inc. directly from SEC EDGAR. electroCore, Inc.'s 13F Pro composite quality score has ranged between 27 and 30 since 2025, currently 27.4 — a stable long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about electroCore, Inc.

Quirks, history, and lore behind ECOR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the low tens of millions of dollars — this is an early-stage commercial company still burning cash as it builds out its commercial infrastructure.
3
The History
Founded in the 2010s, it pioneered a non-implantable, handheld approach to a therapy that traditionally required surgery to implant electrodes near major nerves.
4
The Secret
Its platform targets the vagus nerve from outside the body — no scalpel required — to modulate the nervous and immune systems for a range of conditions.
5
The Lore
The company has explored its technology beyond headaches and into inflammatory diseases and even COVID-related conditions, betting the vagus nerve is medicine's next big frontier.
6
The Giveaway
Its FDA-cleared gammaCore device treats cluster headaches and migraine by delivering gentle electrical pulses to the neck — bioelectronic medicine in the palm of your hand.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$9.6M

Net Income

Q1 2026

$-5.3M

Free Cash Flow

Q1 2026

$-3.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+86.6% YoY

$16.0MFY 2023

FY19 $2.4MFY21 $5.5MFY22 $8.6MFY23 $16.0M

Net Income

+15.0% YoY

$-18.8MFY 2023

FY19 $-45.1MFY21 $-17.2MFY22 $-22.2MFY23 $-18.8M

Operating Income

+15.8% YoY

$-19.3MFY 2023

FY19 $-46.1MFY21 $-20.0MFY22 $-22.9MFY23 $-19.3M

EPS (Diluted)

+27.1% YoY

$-3.42FY 2023

FY19 —FY21 $-4.36FY22 $-4.69FY23 $-3.42

Total Assets

-35.0% YoY

$16.1MFY 2023

FY19 $35.5MFY21 $42.8MFY22 $24.8MFY23 $16.1M

Op. Cash Flow

+11.9% YoY

$-14.7MFY 2023

FY19 $-45.1MFY21 $-13.6MFY22 $-16.6MFY23 $-14.7M

Metric	FY 2023	FY 2022	FY 2021	FY 2019	FY 2018	FY 2017
Revenue	$16.0M +86.6%	$8.6M +57.6%	$5.5M +128.0%	$2.4M +140.7%	$993.0K +22.4%	$811.5K
Net Income	$-18.8M +15.0%	$-22.2M -28.7%	$-17.2M +61.9%	$-45.1M +19.1%	$-55.8M -56.0%	$-35.8M
Operating Income	$-19.3M +15.8%	$-22.9M -14.1%	$-20.0M +56.5%	$-46.1M +15.5%	$-54.6M -112.7%	$-25.6M
EPS (Diluted)	$-3.42 +27.1%	$-4.69 -7.6%	$-4.36	—	—	—
Total Assets	$16.1M -35.0%	$24.8M -42.2%	$42.8M +20.8%	$35.5M -51.8%	$73.5M +87.4%	$39.2M
Operating Cash Flow	$-14.7M +11.9%	$-16.6M -22.1%	$-13.6M +69.8%	$-45.1M +4.3%	$-47.1M -86.0%	$-25.3M

AI Insight: ECOR Financial Trends

Revenue growth accelerated to $10M in Q1 2026 but equity turned deeply negative at -$6M as losses persisted.

• Revenue grew from $6M in Q2 2024 to $10M in Q1 2026, with acceleration from $7M to $10M over recent quarters.

• Operating losses widened from -$3M in Q2 2024 to -$5M in Q1 2026.

• Equity deteriorated sharply from $11M in Q2 2024 to -$6M in Q1 2026.

• $8M debt appeared in Q3 2025, adding leverage to the balance sheet for the first time.

⚠ Operating cash flow turned deeply negative to -$3M in Q1 2026 after improving to -$1M in Q2 2025.

⚠ Company now operating with negative equity of -$6M, indicating potential financing needs.

AI Insight: ECOR Ratio Trends

Operating losses persist with margin deteriorating to -55.5% in Q1 2026 after brief improvement through Q4 2025.

• Operating margin improved from -56.9% in Q1 2025 to -31.8% in Q4 2025 before deteriorating to -55.5% in Q1 2026.

• Net profit margin followed similar pattern, reaching -32.8% in Q4 2025 then worsening to -55.0% in Q1 2026.

• Return on assets improved from -96.1% in Q1 2025 to -65.0% in Q4 2025 but remains deeply negative.

⚠ Sharp margin deterioration in Q1 2026 reverses the improvement trend seen through Q4 2025.

⚠ Missing ROE and ROIC data in recent quarters limits visibility into capital efficiency trends.

Get alerted when ECOR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for electroCore, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ECOR

VANGUARD CAPITAL MANAGEMENT LLC
$1.2M202,644 sh
BALYASNY ASSET MANAGEMENT L.P.
$702.3K116,463 sh
GEODE CAPITAL MANAGEMENT, LLC
$470.9K78,083 sh
Jaffetilchin Investment Partners, LLC
$350.9K58,198 sh
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC
$307.7K46,620 sh
Wealthspire Advisors, LLC
$286.4K47,498 sh
RENAISSANCE TECHNOLOGIES LLC
$267.8K44,409 sh
VANGUARD FIDUCIARY TRUST CO
$232.3K38,528 sh
HighTower Advisors, LLC
$213.1K35,342 sh
BlackRock, Inc.
$161.5K26,776 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	202,644
BALYASNY ASSET MANAGEMENT L.P.	$702.3K	116,463
GEODE CAPITAL MANAGEMENT, LLC	$470.9K	78,083
Jaffetilchin Investment Partners, LLC	$350.9K	58,198
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	$307.7K	46,620
Wealthspire Advisors, LLC	$286.4K	47,498
RENAISSANCE TECHNOLOGIES LLC	$267.8K	44,409
VANGUARD FIDUCIARY TRUST CO	$232.3K	38,528
HighTower Advisors, LLC	$213.1K	35,342
BlackRock, Inc.	$161.5K	26,776

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ECOR on your watchlist

Track score changes the day electroCore, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ECOR a good stock to buy?

13F Pro's AI-powered analysis of electroCore, Inc. (ECOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ECOR are available on the ECOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ECOR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ECOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of electroCore, Inc.'s investment landscape.